{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:36:48Z","timestamp":1761709008482},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T00:00:00Z","timestamp":1406246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40265-014-0271-z","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T10:47:36Z","timestamp":1406198856000},"page":"1659-1672","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["OnabotulinumtoxinA (Botox\u00ae): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury"],"prefix":"10.1007","volume":"74","author":[{"given":"Mark","family":"Sanford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,25]]},"reference":[{"issue":"20","key":"271_CR1","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1212\/WNL.0b013e3181fdabba","volume":"75","author":"EE Benarroch","year":"2010","unstructured":"Benarroch EE. Neural control of the bladder: recent advances and neurologic implications. Neurology. 2010;75(20):1839\u201346.","journal-title":"Neurology"},{"issue":"6","key":"271_CR2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/14740338.2010.501793","volume":"9","author":"R Nicholas","year":"2010","unstructured":"Nicholas R, Young C, Friede T. Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert Opin Drug Saf. 2010;9(6):905\u201315.","journal-title":"Expert Opin Drug Saf"},{"key":"271_CR3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11934-012-0266-9","volume":"13","author":"A Tubaro","year":"2012","unstructured":"Tubaro A, Puccini F, De Nunzio C, et al. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review. Curr Urol Rep. 2012;13:335\u201342.","journal-title":"Curr Urol Rep"},{"issue":"6","key":"271_CR4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11934-011-0221-1","volume":"12","author":"A Sahai","year":"2011","unstructured":"Sahai A, Cortes E, Seth J, et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr Urol Rep. 2011;12(6):404\u201312.","journal-title":"Curr Urol Rep"},{"key":"271_CR5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/jnnp.2008.159178","volume":"85","author":"CJ Fowler","year":"2009","unstructured":"Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med. 2009;85:552\u20139.","journal-title":"Postgrad Med"},{"key":"271_CR6","unstructured":"Andersson K-E, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence: In Abrams P, Cardoza L, Khoury S, Wein A (eds) Incontinence. Health Publication Ltd; 2009. Available from: http:\/\/www.ics.org\/publications\/ici_4\/files-book\/comite-8.pdf ."},{"issue":"1","key":"271_CR7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sc.2011.110","volume":"50","author":"G Popolo del","year":"2012","unstructured":"del Popolo G, Mencarini M, Nelli F, et al. Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients. Spinal Cord. 2012;50(1):8\u201313.","journal-title":"Spinal Cord"},{"issue":"9","key":"271_CR8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00023210-200822090-00002","volume":"22","author":"WJ Schulte-Mattler","year":"2008","unstructured":"Schulte-Mattler WJ. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs. 2008;22(9):725\u201338.","journal-title":"CNS Drugs"},{"key":"271_CR9","unstructured":"Electronic Medicines Agency (emc). BOTOX 100 Allergan units powder for solution for injection: summary of product characteristics. 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/112\/SPC\/BOTOX+100+Units\/ . Accessed 15 July 2014."},{"key":"271_CR10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-3-642-16499-6_17","volume-title":"Urinary tract","author":"A Charrua","year":"2011","unstructured":"Charrua A, Avelino A, Cruz F. Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. In: Andersson K-E, Michel MC, editors. Urinary tract. New York: Springer New York; 2011. p. 345\u201374."},{"issue":"3","key":"271_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.iio.0000167167.10402.74","volume":"45","author":"KR Aoki","year":"2005","unstructured":"Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin. 2005;45(3):25\u201337.","journal-title":"Int Ophthalmol Clin"},{"key":"271_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/TCRM.S33052","volume":"9","author":"K-E Andersson","year":"2013","unstructured":"Andersson K-E. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Ther Clin Risk Manag. 2013;9:161\u201370.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"271_CR13","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.juro.2012.07.001","volume":"188","author":"R Takahashi","year":"2012","unstructured":"Takahashi R, Yunoki T, Naito S, et al. Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats. J Urol. 2012;188(5):1993\u20139.","journal-title":"J Urol"},{"issue":"7","key":"271_CR14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bju.12266","volume":"112","author":"VM Collins","year":"2013","unstructured":"Collins VM, Daly DM, Liaskos M, et al. OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU Int. 2013;112(7):1018\u201326.","journal-title":"BJU Int"},{"issue":"3","key":"271_CR15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","volume":"174","author":"A Apostolidis","year":"2005","unstructured":"Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174(3):977\u201383.","journal-title":"J Urol"},{"issue":"5","key":"271_CR16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1468-1331.2011.03618.x","volume":"19","author":"A Conte","year":"2012","unstructured":"Conte A, Giannantoni A, Proietti S, et al. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Eur J Neurol. 2012;19(5):725\u201332.","journal-title":"Eur J Neurol"},{"issue":"6","key":"271_CR17","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0022-5347(06)00258-8","volume":"175","author":"A Giannantoni","year":"2006","unstructured":"Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 2006;175(6):2341\u20134.","journal-title":"J Urol"},{"issue":"4","key":"271_CR18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","volume":"56","author":"H-T Liu","year":"2009","unstructured":"Liu H-T, Chancellor MB, Kuo H-C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56(4):700\u20136.","journal-title":"Eur Urol"},{"issue":"1","key":"271_CR19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.phrs.2012.11.009","volume":"68","author":"A Giannantoni","year":"2013","unstructured":"Giannantoni A, Conte A, Farfariello V, et al. Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. Pharmacol Res. 2013;68(1):118\u201324.","journal-title":"Pharmacol Res"},{"issue":"3","key":"271_CR20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1464-410X.2011.010362.x","volume":"109","author":"MS Elkelini","year":"2012","unstructured":"Elkelini MS, Bagli DJ, Fehlings M, et al. Effects of intravesical onabotulinumtoxinA on bladder dysfunction and autonomic dysreflexia after spinal cord injury: role of nerve growth factor. BJU Int. 2012;109(3):402\u20137.","journal-title":"BJU Int"},{"issue":"13","key":"271_CR21","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","volume":"25","author":"M Naumann","year":"2010","unstructured":"Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX) across multiple indications. Mov Disord. 2010;25(13):2211\u20138.","journal-title":"Mov Disord"},{"issue":"4","key":"271_CR22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742\u201350.","journal-title":"Eur Urol"},{"issue":"6","key":"271_CR23","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131\u20139.","journal-title":"J Urol"},{"issue":"3","key":"271_CR24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","volume":"81","author":"M Kennelly","year":"2013","unstructured":"Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81(3):491\u20137.","journal-title":"Urology"},{"issue":"1","key":"271_CR25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","volume":"174","author":"B Schurch","year":"2005","unstructured":"Schurch B, de S\u00e9ze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196\u2013200.","journal-title":"J Urol"},{"issue":"6","key":"271_CR26","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229\u201335.","journal-title":"J Urol."},{"issue":"3","key":"271_CR27","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2007.04.026","volume":"52","author":"B Schurch","year":"2007","unstructured":"Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol. 2007;52(3):850\u20138.","journal-title":"Eur Urol"},{"issue":"9","key":"271_CR28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","volume":"30","author":"D Ginsberg","year":"2013","unstructured":"Ginsberg D, Cruz F, Herschorn S, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther. 2013;30(9):819\u201333.","journal-title":"Adv Ther"},{"issue":"3","key":"271_CR29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/nau.22293","volume":"32","author":"D Sussman","year":"2013","unstructured":"Sussman D, Patel V, Del Popolo G, et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242\u20139.","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"271_CR30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1212\/WNL.0b013e3182a2ca4d","volume":"81","author":"MB Chancellor","year":"2013","unstructured":"Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013;81(9):841\u20138.","journal-title":"Neurology"},{"issue":"3","key":"271_CR31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","volume":"55","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55(3):705\u201311.","journal-title":"Eur Urol"},{"issue":"7","key":"271_CR32","first-page":"610","volume":"28","author":"L Malmberg","year":"2009","unstructured":"Malmberg L, Karadzic V. Effects of repeated botulinum toxin A injection therapy in patients with sympthomatic neurogenic detrusor overactivity\u2014a 3-year follow up [abstract no. 168]. Neurourol Urodyn. 2009;28(7):610\u20131.","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"271_CR33","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/nau.21146","volume":"30","author":"H-C Kuo","year":"2011","unstructured":"Kuo H-C, Liu S-H. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourol Urodyn. 2011;30(8):1541\u20135.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"271_CR34","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","volume":"185","author":"S Khan","year":"2011","unstructured":"Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344\u20139.","journal-title":"J Urol"},{"key":"271_CR35","author":"SF Chen","year":"2012","unstructured":"Chen SF, Kuo HC. Lack of consistent therapeutic effects of repeated 200 U onabotulinumtoxina detrusor injections on urinary incontinence in chronic spinal cord injured patients (abstract no. 1656). J Urol. 2012. doi: 10.1016\/j.juro.2012.02.1488 .","journal-title":"J Urol"},{"key":"271_CR36","unstructured":"Panicker J, Schulte-Baukloh H, Del Popolo G, et al. Consistent long-term efficacy of onabotulinumtoxinA in patients with neurogenic detrusor overactivity due to multiple sclerosis: an interim analysis after five treatment cycles [abstract no. 168]. European Committee for Treatment and Research in Multiple Sclerosis; 2\u20135 October 2013; Copenhagen."},{"key":"271_CR37","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1016\/j.juro.2013.02.2963","volume":"1","author":"M Kennelly","year":"2013","unstructured":"Kennelly M, Jenkins B, Zhou J, et al. Consistent and persistent long-term efficacy after repeat onabotulinumtoxinA detrusor injections in patients with neurogenic detrusor overactivity [abstract no. 1717]. J Urol. 2013;1:e706\u20137.","journal-title":"J Urol"},{"issue":"8","key":"271_CR38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/nau.22376","volume":"32","author":"E Rovner","year":"2013","unstructured":"Rovner E, Dmochowski R, Chapple C, et al. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(8):1109\u201315.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"271_CR39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.sc.3101736","volume":"43","author":"K Laet De","year":"2005","unstructured":"De Laet K, Wyndaele J-J. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord. 2005;43(7):397\u20139.","journal-title":"Spinal Cord"},{"key":"271_CR40","unstructured":"Pannek J, St\u00f6hrer M, Blok B, et al. Guidelines on neurogenic lower urinary tract dysfunction. European Association of Urology. 2011. http:\/\/www.uroweb.org\/gls\/pdf\/17_Neurogenic%20LUTS.pdf . Accessed 15 July 2014."},{"key":"271_CR41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pmr.2007.03.005","volume":"18","author":"G Samson","year":"2007","unstructured":"Samson G, Cardenas DD. Neurogenic bladder in spinal cord injury. Phys Med Rehabil Clin N Am. 2007;18:255\u201374.","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"271_CR42","unstructured":"National Institute for Health and Clinical Excellence. Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. 2012. http:\/\/guidance.nice.org.uk\/CG148\/Guidance\/pdf\/English . Accessed 15 July 2014."},{"issue":"1","key":"271_CR43","first-page":"7","volume":"3","author":"A Gomelsky","year":"2011","unstructured":"Gomelsky A, Dmochowski RR. Update on the management of overactive bladder: patient considerations and adherence. J Urol. 2011;3(1):7\u201317.","journal-title":"J Urol"},{"key":"271_CR44","first-page":"CD004193","volume":"1","author":"RS Nicholas","year":"2009","unstructured":"Nicholas RS, Friede T, Hollis S, et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009;1:CD004193.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"271_CR45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrurol.2010.187","volume":"7","author":"C Dowson","year":"2010","unstructured":"Dowson C, Khan MS, Dasgupta P, et al. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol. 2010;7(12):661\u20137.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"271_CR46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-009-0466-1","volume":"28","author":"B Wefer","year":"2010","unstructured":"Wefer B, Ehlken B, Bremer J, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28(3):385\u201390.","journal-title":"World J Urol"},{"issue":"3","key":"271_CR47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","volume":"53","author":"X Gam\u00e9","year":"2008","unstructured":"Gam\u00e9 X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53(3):613\u20138.","journal-title":"Eur Urol"},{"issue":"5","key":"271_CR48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apmr.2007.02.009","volume":"88","author":"B Schurch","year":"2007","unstructured":"Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88(5):646\u201352.","journal-title":"Arch Phys Med Rehabil"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0271-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0271-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0271-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T05:01:52Z","timestamp":1717131712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0271-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,25]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0271-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,25]]}}}